Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRYS NASDAQ:PCVX NASDAQ:PTCT NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$183.36+0.9%$152.43$122.80▼$207.84$5.31B0.64380,397 shs397,457 shsPCVXVaxcyte$42.66+6.3%$32.73$27.66▼$118.62$5.54B1.122.00 million shs2.40 million shsPTCTPTC Therapeutics$65.37+3.7%$54.20$34.57▼$67.40$5.19B0.551.27 million shs2.72 million shsSNDXSyndax Pharmaceuticals$15.60+1.0%$14.61$8.58▼$22.50$1.34B0.681.95 million shs1.77 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech0.00%+9.26%+22.44%+28.21%+3.37%PCVXVaxcyte0.00%+25.54%+32.69%+28.36%-62.66%PTCTPTC Therapeutics0.00%+10.82%+12.69%+34.03%+79.44%SNDXSyndax Pharmaceuticals0.00%-0.51%-3.64%+68.18%-19.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$183.36+0.9%$152.43$122.80▼$207.84$5.31B0.64380,397 shs397,457 shsPCVXVaxcyte$42.66+6.3%$32.73$27.66▼$118.62$5.54B1.122.00 million shs2.40 million shsPTCTPTC Therapeutics$65.37+3.7%$54.20$34.57▼$67.40$5.19B0.551.27 million shs2.72 million shsSNDXSyndax Pharmaceuticals$15.60+1.0%$14.61$8.58▼$22.50$1.34B0.681.95 million shs1.77 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech0.00%+9.26%+22.44%+28.21%+3.37%PCVXVaxcyte0.00%+25.54%+32.69%+28.36%-62.66%PTCTPTC Therapeutics0.00%+10.82%+12.69%+34.03%+79.44%SNDXSyndax Pharmaceuticals0.00%-0.51%-3.64%+68.18%-19.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRYSKrystal Biotech 2.75Moderate Buy$209.0013.98% UpsidePCVXVaxcyte 2.75Moderate Buy$106.25149.06% UpsidePTCTPTC Therapeutics 2.50Moderate Buy$69.005.55% UpsideSNDXSyndax Pharmaceuticals 2.82Moderate Buy$39.22151.42% UpsideCurrent Analyst Ratings BreakdownLatest SNDX, KRYS, PCVX, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025KRYSKrystal BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025PCVXVaxcyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PTCTPTC TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/19/2025SNDXSyndax PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.009/15/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.009/12/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$38.009/10/2025SNDXSyndax PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.009/5/2025SNDXSyndax PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.009/4/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$34.009/3/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$118.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRYSKrystal Biotech$290.52M18.27$4.64 per share39.54$32.90 per share5.57PCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/APTCTPTC Therapeutics$806.78M6.44N/AN/A($14.24) per share-4.59SNDXSyndax Pharmaceuticals$23.68M56.75N/AN/A$3.38 per share4.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRYSKrystal Biotech$89.16M$4.9237.2718.19N/A40.85%15.21%13.81%11/3/2025 (Estimated)PCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.979.38N/AN/A35.65%-106.31%30.61%11/6/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)Latest SNDX, KRYS, PCVX, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07-$0.83+$0.24-$0.83$173.01 million$178.88 million8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 million8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRYSKrystal BiotechN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRYSKrystal BiotechN/A9.689.33PCVXVaxcyteN/A11.1111.11PTCTPTC TherapeuticsN/A3.623.57SNDXSyndax Pharmaceuticals2.064.714.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRYSKrystal Biotech86.29%PCVXVaxcyte96.78%PTCTPTC TherapeuticsN/ASNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipKRYSKrystal Biotech13.70%PCVXVaxcyte3.10%PTCTPTC Therapeutics5.50%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionablePCVXVaxcyte160129.82 million125.80 millionOptionablePTCTPTC Therapeutics1,41079.44 million75.07 millionOptionableSNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableSNDX, KRYS, PCVX, and PTCT HeadlinesRecent News About These CompaniesSyndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA DecisionOctober 4 at 12:17 AM | msn.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)October 3 at 4:01 PM | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $39.22 Average Target Price from BrokeragesOctober 2 at 2:43 AM | americanbankingnews.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 29, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG ResearchSeptember 20, 2025 | marketbeat.comSyndax announces updated NCCN Guidelines for AMLSeptember 19, 2025 | msn.comSyndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute ...September 19, 2025 | finance.yahoo.comSyndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid LeukemiaSeptember 19, 2025 | globenewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 4.8% - Time to Sell?September 17, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at Stifel NicolausSeptember 12, 2025 | marketbeat.comZimmer Partners LP Buys Shares of 213,159 Syndax Pharmaceuticals, Inc. $SNDXSeptember 11, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. $SNDX Shares Bought by Exome Asset Management LLCSeptember 11, 2025 | marketbeat.comInsider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 157,307 Shares of StockSeptember 10, 2025 | marketbeat.comSyndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRCSeptember 10, 2025 | seekingalpha.comSyndax resumed with Buy at Stifel on newly launched drugsSeptember 10, 2025 | msn.comPolar Asset Management Partners Inc. Purchases 21,630 Shares of Syndax Pharmaceuticals, Inc. $SNDXSeptember 9, 2025 | marketbeat.comStocks To Watch: Syndax Pharmaceuticals Sees Relative Strength Rating Jump To 84September 8, 2025 | msn.comSyndax Pharmaceuticals, Inc. $SNDX Shares Purchased by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comGranahan Investment Management LLC Has $6.76 Million Stake in Syndax Pharmaceuticals, Inc. $SNDXSeptember 7, 2025 | marketbeat.comGuggenheim Begins Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)September 6, 2025 | marketbeat.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDX, KRYS, PCVX, and PTCT Company DescriptionsKrystal Biotech NASDAQ:KRYS$183.36 +1.67 (+0.92%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$183.32 -0.05 (-0.02%) As of 10/3/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Vaxcyte NASDAQ:PCVX$42.66 +2.53 (+6.30%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$43.00 +0.35 (+0.81%) As of 10/3/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.PTC Therapeutics NASDAQ:PTCT$65.37 +2.35 (+3.73%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$65.35 -0.02 (-0.03%) As of 10/3/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Syndax Pharmaceuticals NASDAQ:SNDX$15.60 +0.16 (+1.04%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$15.52 -0.08 (-0.54%) As of 10/3/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
